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25 ABSTRACT: To investigate the specific functions of conjugated fatty acids (CFAs) 
26 produced by the probiotic bacterium, α-linolenic acid was isomerized by Lactobacillus 
27 plantarum ZS2058, and two different conjugated α-linolenic acid (CLNA) isomers 
28 were successfully isolated: c9, t11, c15-CLNA (CLNA1) and c9, t11, t15-CLNA 
29 (CLNA2). The effects and mechanism of CLNA crude extract and individual isomers 
30 on colitis were explored. CLNA significantly inhibited weight loss, the disease activity 
31 index, colon shortening. Additionally, CLNA alleviated histological damage, protected 
32 colonic mucous layer integrity and significantly upregulated the concentration of tight 
33 junction proteins (ZO-1, occludin, E-cadherin1 and claudin-3). CLNA significantly 
34 attenuated the level of proinflammatory cytokines (TNF-α, IL-1β, and IL-6) while 
35 upregulating the expression of the colonic anti-inflammatory cytokine IL-10 and 
36 nuclear receptor PPARγ. Moreover, CLNA increased the activity of oxidative stress-
37 related enzymes (SOD, GSH and CAT) and the myeloperoxidase activity was 
38 significantly decreased by CLNA. Meanwhile, the concentrations of CLNA in the liver 
39 and conjugated linoleic acid (CLA) in colonic content were significantly increased 
40 because of the treatment of CLNA. Furthermore, CLNA could rebalance the intestinal 
41 microbial composition of colitis mice, including increasing the α-diversity. CLNA1 and 
42 CLNA2 increased the abundance of Ruminococcus and Prevotella, respectively.
43
44 KEYWORDS: Conjugated linolenic acid (CLNA), Colitis, Intestinal barrier function, 
45 Oxidative stress, Gut microbiota
46
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47  INTRODUCTION
48 Conjugated fatty acids (CFAs), which are defined as the positional and geometric 
49 isomers of unsaturated fatty acids, contain one or more nonmethylene interrupted 
50 double bonds in either cis or trans conformation.1 One CFA that has been intensively 
51 investigated is conjugated linoleic acid (CLA), which exhibits a variety of health 
52 benefits, including anticancer,2-3 antioxidation,4 antiatherosclerotic,5 antidiabetic,6,7 and 
53 antiobesity effects.8-9 In addition to CLA, the conjugated linolenic acid (CLNA) 
54 isomers, which are another type of CFA, have recently received enhancive attention 
55 due to their biological benefits being similar to those of CLA. CLNAs can be collected 
56 from plant oil or bacterial fermentation broth, and plant-derived CLNAs have been 
57 extensively studied, while bacteria-derived CLNAs not yet been studied. The typical 
58 plant-derived CLNAs contain c9, t11, c13-CLNA, c9, t11, t13-CLNA, t9, t11, c13-
59 CLNA, c8, t10, c12-CLNA and t8, t10, c12-CLNA, while typical bacteria-derived 
60 CLNAs contain c9, t11, c15-CLNA and t9, t11, c15-CLNA. Although the cis-trans 
61 properties of the double bonds are different, they all have conjugated double bonds. 
62 Some conjugated double bonds with particular cis-trans properties, such as c9, t11, in 
63 fatty acids can enhance their functionality. In this paper, the isomers of c9, t11, c15-
64 CLNA and t9, t11, c15-CLNA were first separated from the fermentation of L. 
65 plantarum ZS2058, and their function in a mice model was investigated.
66 IBD comprises two types of inflammatory conditions, crohn’s disease (CD) and 
67 ulcerative colitis (UC). Although the mechanism of IBD has not been fully figured out, 
68 several factors are considered in IBD, including immunologic abnormalities, intestinal 
Page 3 of 40
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
69 barrier dysfunction, oxidative stress, and expansion of inflammatory mediators.10-11 
70 Some treatments alleviate IBD by inhibiting inflammation, such as aminosalicylates 
71 and corticosteroids, particularly hydrocortisone, budesonide, prednisone and 
72 antibiotics.12-13 However, there may be some side effects when using anti-inflammatory 
73 drugs, such as headache, abdominal pain, diarrhea and nasopharyngitis.14-16 Currently, 
74 there are some new therapies for IBD which are different from traditional medicine, 
75 such as prebiotics and some microbial metabolites like unsaturated fatty acids.
76 The effects of plant-derived conjugated linolenic acid on colitis have been widely 
77 studied. Tarek Boussetta et al. proved that punicic acid (c9, t11, c13-CLNA) can inhibit  
78 TNF-α-induced priming of NADPH oxidase, which is related to the 
79 p38MAPKinase/Ser345-p47phox-axis and MPO release.17 C9, t11, t13-CLNA can 
80 improve DSS-induced colitis in mice by improving the level of peroxisome-activated 
81 receptor-γ (PPARγ).18 The structures of c9, t11, c15-CLNA (CLNA1) and t9, t11, c15-
82 CLNA (CLNA2) were exactly similar to plant-derived CLNA; therefore, they may have 
83 similar effects on colitis. To date, there was only in vitro experiments on Lactobacillus-
84 derived CLNA, which have proved that it can inhibit the growth of SW480 cells and is 
85 more toxic than LNA and CLA.19-20 No study has reported the efficacy of the two 
86 isomers in vivo, perhaps due to the difficulty of screening high-yield CLNA strains and 
87 the complexity of extracting and separating CLNA isomers. Therefore, one of the 
88 purposes of this study is to explore the function of CLNA1 and CLNA2 in colitis and 
89 provide a medical basis for the use of conjugated fatty acids as adjuvants in the 
90 treatment of colitis. In addition, different isomers usually showed different bioactivity 
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91 due to cis, trans configurations of their double bonds.21 For example, all-trans 
92 conjugated fatty acids have more effective tumor suppressing activity.22 Therefore, the 
93 other purpose of this study was to explore the difference between the two isomers in 
94 colitis.
95  MATERIAL AND METHODS
96 Microorganism Cultivation and Preparation of the CLNA Mixture. L. plantarum 
97 ZS2058 was subcultured twice in de Man, Rogosa and Sharpe (mMRS) medium at 37℃ 
98 for 24 h, inoculated into 2 L of mMRS with α-linolenic acid (Nu-check Prep, Elysian, 
99 MN) at a final concentration of 30 mg/ml, and cultured for 48 h. After culturing, the 
100 fermentation broth was placed in a pear-shaped separatory funnel with the ratio of 
101 fermentation broth:isopropanol:n-hexane = 3:2:3 (v/v/v), shaken thoroughly, and 
102 allowed to stand for 15 min. The solution was layered, and the upper transparent n-
103 hexane layer was collected. The n-hexane layer was then evaporated on a rotary 
104 evaporator and redissolved in methanol (chromatography grade) to a concentration of 
105 40 mg/mL.
106 Separation of CLNA and Purity Detection. The crude extracts were separated by RP-
107 HPLC on an Ultimate® 5 μm C30 semipreparative column (10×250 mm) (Yuexu 
108 Technology, Shanghai, China) by a Waters 2545 RP-HPLC. The CLNA isomers were 
109 separated in methanol:water:formic acid (80:20:0.01, vol/vol) at a flow rate of 5 
110 mL/min with an injection volume of 700 μL. The CLNA fragments were detected by a 
111 UV detector at absorbances of 205 nm and 233 nm, and fractions containing the single 
112 isomer were collected automatically when both absorbances were detected. The 
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113 methanol and water from the pooled fractions were removed by rotary evaporation 
114 (37℃), and then the single CLNA isomer was re-extracted with methanol for storage. 
115 The purities of the extracted CLNA1 (c9, t11, c15-CLNA) and CLNA2 (t9, t11, c15-
116 CLNA) were determined by GC-MS as previously described.23
117 Animals and Diets. Seven-week-old male C57 BL6/J mice were housed in the Animal 
118 Housing Unit of Jiangnan University for one week to adapt. The mice were maintained 
119 at a room temperature of 23-25℃, room humidity of 40-70% and a 12-h light/dark cycle. 
120 The mice were kept in standard laboratory IVC cages, where sterile water and standard 
121 laboratory chow were provided libitum.
122 The fatty acids were dissolved in skim milk and oral gavaged, and the composition 
123 of fatty acids of every group were listed in Table 1. All the animals were fed with 
124 standard laboratory chow; its component was listed in Table 2. The detailed 
125 experimental protocols were as follows: 72 C57BL6/J male mice were randomly 
126 divided into 9 groups: control (no DSS), DSS + vehicle, DSS + α-linolenic acid (ALA), 
127 DSS + punicic acid (PA), DSS + CLNA mixture, vehicle + CLNA mixture (no DSS), 
128 DSS + CLNA1, DSS + CLNA2, DSS + drug (mesalazine, 5-aminosalicylic acid). Fatty 
129 acids, drugs or vehicle was given once a day by gavage from days 1 to 14. All the fatty 
130 acids were emulsified in 10% skim milk, and the dose of every type of CLNA isomer 
131 was 400 μg/d. 400 μg/d was the dose of pure isomer to ensure the effective contrast. 
132 The CLNA mixture and PA (Jian HaiRui Co., Ltd, Jian, China) was quantified by the 
133 purity. 5-aminosalicylic acid (Etiasa Pharmaceutical Co., Ltd., Saint-Cloud, Paris, 
134 France) was dissolved in PBS, 5 mg/d. DSS (MP Biomedicals, LLC, Irvine, CA) was 
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135 dissolved in the water and was given from days 7 to 14. The animal experiment protocol 
136 has been approved by the Ethics Committee of Jiangnan University, China (JN. 
137 No.20181130c0900515[258]) and in compliance with the Directive of 
138 2010/63/European Community.
139 Induction and Assessment of Colitis. The dextran sodium sulfate was dissolved in 
140 drinking water for mice at a concentration of 3% to induce the colitis.24 Mice were 
141 allowed to drink freely and DSS water was replaced daily. During DSS treatment from 
142 days 7 to 14, the stool consistency, weight loss, and hematochezia were detected daily 
143 to determine the disease activity index (DAI)25-26. The occult blood in the feces was 
144 measured by an Occult Blood kit (Nanjing Jiancheng Co., Ltd., Nanjing, China). The 
145 standard for evaluation of the disease activity index were listed in the Table 3. And the 
146 mice were sacrificed at the day 15. The Carnoy’s solution (ethanol:chloroform:acetic 
147 acid, 6:3:1, vol/vol/vol) was used to fix the colon segments at 4°C for 8 h. Then the 
148 colon tissue was embedded in paraffin, sectioned (5 mm) and stained with alcian blue 
149 or H&E staining. Pannoramic MIDI Digital Slide Scanner (3D Histech Co., Ltd., 
150 Budapest, Hungary) was used to scan and capture the images of the dyed sections. The 
151 severity of colonic histological damage in each mice was graded and the valuation 
152 system of pathological scores was based on a previously reported method.27 
153 Biochemical Assays. The frozen colons stored at -80°C were weighed and 
154 homogenized in saline solution by a high flux tissue crushing instrument. Then the 
155 homogenate was centrifuged at 12,000 g, 4°C for 10 min. The activity of 
156 myeloperoxidase (MPO) in colon was detected by commercially available kits (Nanjing 
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157 Jiancheng Co., Ltd., Jiangsu, China) according to the manufacturer’s instructions. The 
158 activity of antioxidant enzymes (SOD, GSH, CAT) were assessed by enzyme-linked 
159 immunosorbent assay (ELISA) kits (Nanjing SenBeiJia Biotechnology Co., Ltd., 
160 Jiangsu, China). The total protein concentration in tissue homogenate was measured by 
161 the BCA protein assay kit (Beyotime Biotechnology, Shanghai, China). In the result of 
162 MPO and antioxidant enzymes, the activity were presented in the form of U/g colon 
163 protein and U/mg colon protein respectively. 
164 Level of Cytokines in Colon Tissues. The frozen colons stored at -80°C were weighed 
165 and homogenized in potassium phosphate containing 1% phosphatase inhibitor and 1% 
166 protease inhibitors (Beyotime Biotechnology, Shanghai, China). Then, the cytokines 
167 IL-10, IL-1β, IL-6, and TNF-α were detected by the R&D ELISA Kit (R&D Systems, 
168 Minneapolis, MN) according to the instructions. The total protein concentration in 
169 tissue homogenate was measured by the BCA protein assay kit (Beyotime 
170 Biotechnology, Shanghai, China), and the results were presented in the form of pg/mg 
171 total colon protein.
172 Tight Junction Protein Bioassays. The concentrations of E-cadherin 1, occludin, ZO-
173 1, and claudin-3 in colon tissue homogenate were measured by commercially available 
174 ELISA kits (Nanjing SenBeiJia Biotechnology Co., Ltd., Nanjing, Jiangsu, China). The 
175 results were presented in the form of pg/ml colon homogenization buffer.
176 Fatty Acid Analysis. The liver and colonic content were weighed and homogenized in 
177 potassium phosphate, then the fatty acids were extracted and methylated as previously 
178 described. Then fatty acid methyl ester were dissolved in hexane and detected by gas 
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179 chromatography (GC)−mass spectrometry (the parameters of the instrument were as 
180 previously described).28,29
181 Mouse Fecal Genome Extraction and Analysis. A certain amount of mouse feces was 
182 weighed, and the genome was extracted with a Fast DNA Spin Kit for Feces (MP 
183 Biomedicals, LLC, Irvine, CA). After extraction, the V3−V4 region of the 16S 
184 ribosomal RNA (rRNA) gene was PCR-amplified using the primers 341F: 5′-
185 CCTAYGGGRBGCASCAG-3′ and 806R: 5′-GGACTACNNGGGTATCTAAT-3′, 
186 nucleic acid electrophoresis was carried out using the PCR products, and the 
187 corresponding strip was purified by the QIA quick Gel Extraction Kit (Qiagen, 
188 Germany). Both the genome extraction kit and the DNA purification kit were performed 
189 according to the manufacturers’ instructions. After sequencing, bioinformatics analysis 
190 of the 16S rRNA sequence data was carried out as previously described.30
191 Statistical Analysis. All data are presented as the mean ± SEM of each group (n=8). 
192 The statistical significance between DSS group and other groups were analyzed by 
193 SPSS 19.0 software (SPSS Inc., Chicago, IL) in the arithmetic ANOVA. A p value of 
194 <0.05 indicates a significant difference. Data analysis was performed and mapped by 
195 GraphPad Prism 7 (GraphPad software, Inc.) Microbiota-related analyses were 
196 conducted by QIIME and R 3.5.0. Linear discriminant analysis (LDA) effect size 
197 (LEfSe) was performed by Python 2.7 and R 3.5.0.
198  RESULTS
199 Preparation and Detection of c9, t11, c15-CLNA and c9, t11, t15-CLNA. The α-
200 linolenic acid was isomerized by L. plantarum ZS2058, which can transform 
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201 approximately 60% of ALA into CLNA31, then the CLNA mixtures were extracted 
202 from the fermentation. Fatty acids with conjugated double bonds are characterized by 
203 an absorption peak at 233 nm. Fragment ion peak signals for these two isomers are m/z 
204 292 and 261. A total of 600 mg of c9, t11, c15-CLNA (CLNA1) and c9, t11, t15-CLNA 
205 (CLNA2) was collected by preparative liquid chromatography. The purities of CLNA1 
206 and CLNA2 were 93.09% and 94.09%, respectively, and the chemical structures of the 
207 two isomers are shown in Figure 1C. The cis-trans property of the C15 double bond of 
208 CLNA1 and CLNA2 was different. The double bond positions in plant-derived CLNAs 
209 were universally located at C9, C11, C13, while the Lactobacillus-derived CLNA in the 
210 current study was located at C9, C11, C15.
211 CLNA1 and CLNA2 Alleviate DSS-induced Colitis in Mice. The changes in the 
212 body weight and disease activity index (DAI) were measured daily during DSS 
213 treatment, and the colon length was measured after the mice were euthanized. Four days 
214 after DSS administration, the weight of the mice began to drop dramatically, and the 
215 final weight was 8.3% lower than the initial weight. Feeding the mice with CLNA 
216 mixture, CLNA1 and CLNA2 showed 5.7%, 6.0% and 7.0% weight loss, respectively 
217 (Figure 2A), demonstrating that the weight loss of the other groups was relieved 
218 compared with that of the DSS group. With the treatment of DSS, the body weight loss 
219 and DAI of mice increasing daily (Figure 2B).
220 The DAI indicates the severity of colitis during modeling in mice. The DSS group 
221 presented the highest DAI, which manifested the most serious weight loss, diarrhea and 
222 gross bleeding. The DAI was considerably reduced in the other six groups, but ALA 
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223 showed a relatively weaker effect. At the end of the experiment on day 14, the DAI for 
224 the DSS group reached a mean of 9.38, while oral administration of CLNAs, PA and 
225 drug markedly decreased the DAI to approximately 5.25.
226 Colon length characterizes the degree of inflammation in colon tissue and is an 
227 important indicator in colitis models. DSS challenge led to colon length shortening by 
228 22.9% compared to that of the control group, whereas punicic acids and CLNA2 
229 resulted in colon shortening by 12.1% and 16.8% compared to the control group. This 
230 indicated that CLNA appeared to significantly recover the colon length. Pretreatment 
231 with CLNA1 (5.31±0.181) and CLNA mixture (5.18±0.120) appeared to partially 
232 recover the colon length, but not significantly (Figure 2C).
233 H&E staining was used to observe histopathological injury (Figure 2D). In normal 
234 mice, the colon mucosa is intact, the villi are neat, and the crypt structure is healthy. 
235 The goblet cells were abundant in the colon tissue of normal mice, and no inflammatory 
236 cell infiltration or mucosal erosion can be observed. However, in the mice with colitis, 
237 increased loss of submucosal structures, epithelial crypts and irregular crypts as well as 
238 more widespread bowel edema can be observed. These characteristics in DSS colon 
239 tissue mean that the colitis model was successfully established. The histological injury 
240 score (Figure 2E) was evaluated based on the H&E staining images, and the score 
241 showed quantifiable results of tissue damage. The score of the mice in DSS group (9.67 
242 ± 0.25) was significantly higher than normal mice (0.00 ± 0.00) (P < 0.0001). 
243 Treatments with CLNA1, CLNA mixture and PA significantly reduced the 
244 inflammation score of the colon. This indicated that CLNA either from Lactobacillus 
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245 or plants can relieve inflammatory cellular infiltration, submucosal edema, loss and 
246 hyperplasia of crypts, and severe epithelial structure damage. From the results of 
247 histopathological score, CLNA1 showed the most effective protection on the injury of 
248 colon tissue. Tissue damage was reduced by treatment with ALA, which indicated 
249 weaker effects compared to CLNA1 and CLNA mixture. And the drug also showed a 
250 significant remission of colon tissue, which showed that the positive control group 
251 made sense.
252 CLNA1 and CLNA2 Regulate Inflammatory Cytokine Level in Colonic Tissue. To 
253 evaluate the effects of CLNA on inflammatory cytokines, the level of proinflammatory 
254 cytokines and anti-inflammatory cytokines in colonic tissue was analyzed. Treatment 
255 with DSS significantly increased the level of the cytokines IL-1β (Figure 3A), TNF-α 
256 (Figure 3B) and IL-6 (Figure3D), whereas oral administration of CLNAs markedly 
257 inhibited the DSS-induced upregulation of cytokine concentrations. Notably, TNF-α, 
258 the most significant proinflammatory cytokine, decreased by 1.45-fold by CLNA1, 
259 1.82-fold by CLNA2 and 1.92-fold by drug in the colon compared to the DSS group. 
260 DSS significantly reduced the expression of IL-10 (Figure 3C), whereas this change 
261 was attenuated by CLNAs. PPAR-γ (Figure 3E) showed no significant change between 
262 the control, CLNA control, DSS and drug groups. However, the other five groups 
263 treated with various C18:3 fatty acids all showed an increase in the expression of 
264 PPAR-γ, which indicated that this change was characteristic of fatty acids. In particular, 
265 the effects of CLNA1 (77.53 ± 3.82) and CLNA mixture (70.247 ± 5.52) on PPAR-γ 
266 were more obvious compared to the DSS group (56.99 ± 1.28).
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267 CLNA1 and CLNA2 Protect the Colonic Mucous Layer and Epithelium Structure. 
268 To investigate the effects of CLNAs on the mucous layer and goblet cells, the protein 
269 of mucin2 (MUC2) was measured (Figure 4B). The concentration of MUC2 showed a 
270 significant reduce in the DSS-treated mice (278.04 ± 6.31), whereas CLNA1 
271 (339.28±6.47), CLNA2 (343.78±5.92) and ALA (330.13±6.03) treatments maintained 
272 its content at normal levels compared with levels in the control group (334.90±11.78). 
273 Other groups also indicated a tendency of protection on the mucous layer compared to 
274 the DSS group, although there was no significant difference. In the DSS group, the 
275 colon tissue slice stained by alixin blue (Figure 4A) showed that the mucin produced 
276 by goblet cells were severely damaged. CLNA1, CLNA2 and CLNA mixture 
277 significantly protected against the destruction of the mucosal layer, which were stronger 
278 than ALA at the same dose. 
279 To evaluate the effects of CLNAs on the epithelium structure, the expression of 
280 tight junction proteins, including ZO-1 (Figure 4C), occludin (Figure 4D), E-
281 cadherin1 (Figure 4E), claudin-3 (Figure 4F), and in the colon was measured. 
282 Treatment with mesalazine, CLNA1, CLNA2, CLNA mixture and ALA significantly 
283 increased the concentrations of the four key TJ proteins compared with the DSS group. 
284 Moreover, the protective effects of CLNAs on E-cadherin 1 and claudin-3 were stronger 
285 than mesalazine. From the overall results of the four TJ proteins, the PA displayed a 
286 weaker protective effect on the intestinal barrier compared with CLNAs, which 
287 indicated that the CLNAs derived from Lactobacillus may be better than those from 
288 plants. There was no obvious difference between the CLNA1, CLNA2, and CLNA 
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289 mixture groups, so it is impossible to conclude which isomer is more potent.
290 CLNA1 and CLNA2 Regulated Oxidative Stress. Oxidative stress is the essential 
291 cause of cell and tissue damage. It can result in abnormal metabolism of oxygen free 
292 radicals and excessive activation of apoptosis. Oxygen free radicals could result in the 
293 release of inflammatory mediators.32 And many papers have reported that plant-derived 
294 CLNA showed an antioxidant activity.33 To investigate the influence of Lactobacillus 
295 derived CLNAs on oxidative stress, CAT activity (Figure 5A), SOD activity (Figure 
296 5B) and GSH-PX (Figure 5C) activity in the colon were measured. All these enzymes 
297 play key roles in protecting cells from damage induced by inflammation and oxidative 
298 stress. There was no significant change between the control, DSS and CLNA control 
299 groups. However, increased levels of the three indexes were observed in the other 
300 treatment groups. Treatment with CLNA1 significantly increased SOD and GSH 
301 activity 1.29- and 1.48-fold compared with DSS treatment, respectively. In addition, 
302 CLNA2 could significantly increase the level of CAT 1.27-fold compared with DSS. 
303 The activity of SOD and GSH-PX in colon tissues were significantly increased by 
304 CLNA1, while CLNA2 significantly increased CAT activity, which indicated that 
305 CLNA alleviated colitis by inhibiting oxidative stress. In addition, CLNA1 showed a 
306 more remarkable influence on oxidative stress. These results were similar to those of 
307 studies on plant-derived CLNA. PA and α-ESA have been proven to reduce oxidative 
308 stress and lipid peroxidation and restore antioxidant enzymes such as superoxide 
309 dismutase, catalase, and glutathione peroxidase.34 Treatment with ALA or PA could 
310 induce a higher activity of CAT and SOD. For the drug control group, CAT activity 
Page 14 of 40
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
311 showed an obvious improvement compared to other groups. To evaluate the effects of 
312 CLNA on colonic inflammatory enzymes, the activity of MPO in colon, which can 
313 reflect neutrophil infiltration, was measured. All the treatments in this experiment can 
314 significantly decrease the activity of MPO induced by DSS. Only ALA group showed 
315 a relatively weak effect on MPO compared with other treatment groups (Figure 5D).
316 The Fatty Acid Composition in the Blood, Liver and Colonic Contents. To evaluate 
317 the distribution of orally administered CLNA in mice, the composition of fatty acids in 
318 blood, liver and colonic contents was analyzed. The composition of fatty acids in blood 
319 showed no significant difference among the nine groups (Figure 6A). No CLNA or 
320 CLA was detected in the blood, which may be due to the content being too low to detect 
321 or the conjugated fatty acids being metabolized at the point of blood collection. There 
322 was a considerable change in liver and colonic contents, which mainly focused on the 
323 proportion of CLA or CLNA in total fatty acids. In the liver, the percentages of CLNA 
324 in total fatty acids from the CLNA control and CLNA mixture groups were 3.04±0.17 
325 and 1.48±0.23, respectively, which manifested an increase compared to the control 
326 (2.39±0.38) and DSS groups (0.70±0.12) (Figure 6B). Other five groups showed no 
327 significant differences on the content of CLNA in liver compare to DSS group. 
328 Interestingly, unlike the liver, there was no significant difference in the ratio of CLNA 
329 in colonic contents between the nine groups. However, the ratio of CLA in total fatty 
330 acids increased significantly in the CLNA treatment group. The CLNA Mix group 
331 (1.74±0.22) showed the most obvious enhancement in the CLA ratio, which was 3.28-
332 fold compared with that of the DSS group (0.55±0.11). In addition, the CLNA control 
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333 group also showed an increase in the CLA percentage at 0.77±0.06 compared with the 
334 control group at 0.09±0.09. These results indicated that CLNA was eventually 
335 metabolized into CLA in the contents of the colon. (Figure 6C). Another interesting 
336 result indicated that the DSS group showed a higher CLA content than the control group, 
337 while the content of CLA in the CLNA mixture group was also higher than that in the 
338 CLNA control group. This may be because DSS-induced colitis can result in the 
339 production of CLA. In addition, ALA can also significantly increase the composition 
340 of CLA. Whereas PA group was similar to drug group without significant increase on 
341 the content of CLA.
342 CLNA1 and CLNA2 Influenced the Intestinal Microbiota. To determine the 
343 correlation between gut microbiota and the effects of CLNA treatment, the gut 
344 microbiota of mice treated with CLNAs, DSS, PA, ALA, and mesalazine and the 
345 control group were studied based on 16S rDNA amplicon sequencing. The microbial 
346 distribution of nine groups on the phylum level was analyzed (Figure 7A). Compared 
347 with the control group, the intestinal microbial structure of mice in the DSS group 
348 changed significantly. The predominant phyla in control group were Bacteroidetes 
349 (68.19%), Firmicutes (20.09%) and Verrucomicrobia (6.36%) (Figure 7A). However, 
350 DSS treatment dramatically altered the bacterial composition at the phylum level, and 
351 the relative abundance of Proteobacteria increased from 0.92% to 16.33%, while the 
352 relative abundances of Bacteroidetes and Verrucomicrobia decreased to 53.64% and 
353 4.67%, respectively (Figure 7A). The proportion of Firmicutes showed no significant 
354 change. However, CLNA1 significantly increased the abundance of Firmicutes. And 
Page 16 of 40
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
355 there was a great improvement on the abundance of Deferribacteres in drug group 
356 (5.18%) compared to that in DSS group (1.27%).
357 α-Diversity was evaluated by the Chao1 and Shannon indexes (Figure 7B). Chao1 
358 reflects the community richness of species within a single sample, while the Shannon 
359 index represents microbial diversity. The Chao1 and Shannon indexes in the DSS group 
360 were much lower than those in the control group, and they were significantly increased 
361 by drug treatment. In addition, the Chao1 of the CLNA1, CLNA mixture and ALA 
362 groups was also significantly different from that of the DSS group.
363 The gut microbiota diversity among different groups was analyzed by the LDA 
364 effect size (LEfSe) (Figure 7C, 7D). The LDA score histogram was drawn to identify 
365 statistically significant biomarkers and reveal the dominant microorganisms in each 
366 group. The proportion of major bacterial communities largely shifted within the 
367 different treatment groups. Among them, Turicibacter was dominant in the DSS group; 
368 Firmicutes was dominant in the CLNA control group; Parabacteroides and 
369 Porphyromonadaceae were the dominant microbes in the CLNA mixture group; and 
370 Clostridiales and Clostridia were dominant microbes in the CLNA1 group. Bacteroides 
371 and Bacteroidaceae were the dominant microbes in the ALA group. Prevotellaceae and 
372 Provetella were dominant microbes in the CLNA2 group. DSS significantly decreased 
373 Bacteroidetes and increased Proteobacteria. However, there was no dominant 
374 microorganisms in drug control, which meant the abundance of microorganisms in drug 
375 control showed no significant superiority compared with other groups. Furthermore, 
376 the correlations between the colonic CLA concentration, TJ proteins, differential 
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377 microorganisms, and inflammation markers were analyzed. Colon length, histological 
378 scores, MPO, and DAI were the characteristic index in colitis and had higher weightings 
379 in the network analysis (Figure 7E). The concentration of colonic CLA positively 
380 correlated with Desulfovibrio and Enterobacter but negatively correlated with 
381 Coprococcus.
382  DISCUSSION
383 Probiotics have been claimed to possess functions such as suppressing inflammation, 
384 protecting the intestinal barrier, and increasing the body’s antioxidant capacity.35-36 The 
385 benefits of probiotics have been attributed to certain beneficial metabolites produced 
386 by them. In this study, we used Lactobacillus plantarum ZS2058 to isomerize α-
387 linolenic acid and assess the function of the CLNA produced. The structure of 
388 Lactobacillus-derived CLNA is different from that of plant-derived CLNA, and they 
389 can be defined as a new material synthesized by bacteria. Until now, CLNA1 and 
390 CLNA2 have not been comprehensively studied, and there have been no functional in 
391 vivo studies on any Lactobacillus-derived single isomer of CLNA.
392 There was no abnormality in the control mice fed the CLNA mixture; therefore, it 
393 was speculated that the CLNA mixture was safe for 14 days of gavage. Tom et al. added 
394 30.33% CLNA (c9, t11, c15-CLNA + c9, t13, c15-CLNA) to the diet of neonatal pigs 
395 and concluded that short-term intake of CLNA was safe.37 In addition, the weight of 
396 the mice after 14 days of gavage of the CLNA mixture was less than that of the control 
397 mice, indicating that Lactobacillus-derived CLNA can lower body weight and weight 
398 gain. This is similar to the effect of plant-derived CLNA, such as punicic acid or α-
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399 ESA, on obese mice.38-40 From the results of the composition of conjugated fatty acids 
400 in the blood, liver and colonic contents, there was no obvious change in the blood. 
401 Hiroyuki reported that the inhibition of colonic tumors by pomegranate seed oil (70% 
402 c9, t11, c13-CLNA) was associated with an increased content of c9, t11-CLA in the 
403 lipid fraction of the colonic mucosa and liver.41 CLA has been thoroughly certified to 
404 alleviate colon cancer or colitis, so the function of CLNA may partially be due to the 
405 increase in CLA in mice. In our study, the CLNA significantly increased in the liver, 
406 while the CLA significantly increased in the colonic contents of mice given CLNA. We 
407 hypothesized that CLNAs may be converted to CLA in the gut of mice.
408 PPARs are receptors for endogenous lipid molecules representing promising new 
409 targets for the treatment and prevention of IBD.42 PPARγ can inhibit the activation and 
410 nuclear import of NF-κB by the IkB-α pathway in which NF-κB plays a key role in the 
411 regulation of the inflammatory response and pathogenesis of IBD.43 PPAR-gamma is 
412 also an important target during the conjugated linolenic acids work on some diseases 
413 like IBD and obesity.42 The expression of PPAR-γ in mice treated with CLNA1 and 
414 CLNA mixture was significantly increased compared with the control group. This was 
415 consistent with the plant-derived CLNA and CLA. The loss of functional PPARγ or 
416 PPARδ impaired the anti-inflammatory effects of punicic acid, such as upregulated 
417 Foxp3 expression in T-cells and suppressed TNF-α.44 α-ESA was also identified as a 
418 natural PPARγ agonist and found to be effective in ameliorating disease-associated 
419 phenotypes in mice with DSS colitis.45 Bassaganya Riera et al. used PPARγ knockout 
420 mice to prove that CLA was able to reduce colitis by activating PPARγ.46 CLA induced 
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421 apoptosis in HT-29 and Caco-2 cells by upregulating PPARγ.47 CLA in the colon 
422 targeted myeloid cell PPARγ to suppress colitis.48 Overall, the CLNA1 and CLNA 
423 mixture alleviated colitis by targeting PPARγ to reduce inflammation, while CLNA2 
424 showed an ambiguous effect on PPARγ.
425 A physical barrier was formed by the epithelium and the mucosal layer to avoid 
426 the potentially toxic and noxious agents to disseminate into the underlying tissue, which 
427 induced the inflammation in the colon. The alteration in cytokine profiles, in turn, 
428 further trigger the decline in tight junctions. Therefore, a vicious cycle of mucosal 
429 barrier dysfunction and inflammation is established.49-50 Treatments with 
430 Lactobacillus-derived CLNAs increased the concentration of MUC2, contributing to  
431 the integrity of the colonic mucous layer and goblet cells. Tight junction proteins 
432 connect enterocytes and play an important role in the integrity of the intestinal barrier.51 
433 The CLNA1, CLNA2 and CLNA mixture significantly upregulated TJ proteins (E-
434 cadherin 1, ZO-1, claudin-3, and occludin) and CLNA1 showed a stronger role in 
435 protecting the intestinal barrier than PA. Lactobacillus-derived CLNA also manifested 
436 stronger regulation of the expression of relative cytokines than PA. As for the level of 
437 cytokine, PA just showed significance on IL-6, but Lactobacillus derived CLNA 
438 showed significance on IL-β, TNF-α and PPAR-gamma. So Lactobacillus-derived 
439 CLNA showed more effective influence against colitis based on the TJ protein and 
440 cytokine results. However, no obvious difference was observed in the expression of TJ 
441 proteins and cytokines between the CLNA1 and CLNA2 groups.
442 Interaction disorder between intestinal microbes has been confirmed as a critical 
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443 defect resulting in intestinal inflammation.52 In the current study, DSS decreased 
444 bacterial species richness and shifted the bacterial community composition. The 
445 CLNA1 isomer significantly increased the α-diversity, and the CLNA control group 
446 was more diverse than the control group. A higher abundance of the phylum 
447 Verrucomicrobia was observed in the CLNA2 and ALA groups, which was more than 
448 twice as abundant as the DSS group. Verrucomicrobia was considered to be associated 
449 with the higher expression of MUC2.53 In humans, there is an overall trend toward 
450 lower biodiversity and decreased abundance of Firmicutes in people with IBD 
451 compared with controls.54 CLNA1 increased the abundance of the phylum Firmicutes 
452 approximately 1.5 times compared with the DSS group. At the genus level, CLNA1 
453 treatment significantly increased the abundance of Parabacteroides and Dorea. 
454 CLNA2 increased the abundance of Prevotella, which had a positive association with 
455 the control group.55 Ce´line et al. reported that PUFA-derived bacterial metabolites, 
456 including CLNA and CLA, were positively correlated with specific fecal bacteria 
457 (Bifidobacterium spp., Eubacterium ventriosum and Lactobacillus spp.).56 The 
458 abundance of Bifidobacterium was exactly improved in the CLNA control group. 
459 Bacteroides fragilis strains can invade intestinal tissues and cause damage.57 DSS 
460 significantly increased the abundance of Bacteroides compared to the control and 
461 CLNA control groups; however, no significant decrease was observed in the other 
462 treatment groups. Thus, our results indicated that CLNA treatment partially prevented 
463 the microbiota changes induced by DSS.
464 In the current study, c9, t11, c15-CLNA and c9, t11, t15-CLNA were proven to 
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465 alleviate colitis in mice and have different functions compared with other fatty acids. 
466 From the weight loss, colon length, DAI and pathological scores, CLNA1, CLNA mix 
467 and PA showed relatively stronger effects on colitis, while CLNA2 and ALA showed 
468 relatively week effects. For cytokines, mucin protein, tight junction proteins and 
469 antioxidant enzymes, CLNA1 and CLNA mixture showed a strong regulation on those 
470 indexes, while CLNA2, PA and ALA showed a relatively week regulation. The primary 
471 mechanisms of relieving DSS-induced colitis by the two isomers involved inhibiting 
472 proinflammatory factors, protecting mucosal barriers, and regulating oxidative stress 
473 and intestinal microbial damage. CLNA entered the bowel lumen and then increased 
474 the concentration of CLA, which could relieve colitis through all of the above aspects.30 
475 Furthermore, CLNA in the bowel lumen improved the activity of antioxidant-related 
476 enzymes, which could improve the intestinal barrier. At the same time, CLNA could 
477 directly enter into the mucus layer and epithelial cells to regulate MUC2 and TJ proteins. 
478 In addition, CLNA can enter the lamina propria of mice and regulate the levels of pro-
479 inflammatory or anti-inflammatory cytokines to reduce the inflammatory response. 
480 CLNA could increase the α-diversity in colonic contents and regulate the bacterial flora. 
481 These results will assist us explore the mechanism of CLNAs to reduce colitis and 
482 investigated the mechanism of CLNA regulating other immune-related diseases, so as 
483 to guide the further development of CLNA research.
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664   FIGURE CAPTIONS
665 Figure 1. Preparation and purity detection of CLNA1 and CLNA2.
666 (A) Separation of CLNA1 and CLNA2 by liquid chromatograph. (B) Mass spectrum of 
667 CLNA1 and CLNA2. (C) Chemical structures of conjugated linolenic acid (CLNA) 
668 isomers used in this study (CLNA1: c9, t11, c15-CLNA, CLNA2: t9, t11, c15-CLNA).
669
670 Figure 2. Symptoms of DSS-induced colitis.
671 (A) Body weight, (B) disease activity index (DAI), (C) colon length, (D) histological 
672 examination (the scale bars are 200 μm). (E) colonic histological injury.
673 Data are presented as mean ± SEM (n =8 mice per group). *: p < 0.05, **: p < 0.01 and 
674 ***: p < 0.001, ****: P < 0.0001 compared with DSS group.
675
676 Figure 3. Effects of CLNA on inflammatory cytokines in colonic tissues.
677  (A) IL-1β, (B) TNF-α, (C) IL-10, (D) IL-6, and (E) PPAR γ.
678 Data are presented as mean ± SEM (n =8 mice per group). *: p < 0.05, **: p < 0.01 and 
679 ***: p < 0.001, ****: p < 0.0001 compared with DSS group.
680
681 Figure 4. Effects of CLNA on the mucous layer.
682 (A) Alcian blue staining (scale bar = 200 μm), (B) concentration of MUC2, (C) 
683 expression of ZO-1 in colon, (D) expression of Occludin in colon, (E) expression of E-
684 cadherin1 in colon, (F) expression of Claudin-3 in colon.
685 Data are presented as mean ± SEM (n =8 mice per group). *: p < 0.05, **: p < 0.01 and 
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686 ***: p < 0.001, ****: P < 0.0001 compared with DSS group.
687
688 Figure 5. Effects of CLNA on the activity of oxidative-stress-related enzymes in 
689 the colon.
690 (A) CAT, (B) GSH, (C) SOD, and (D) MPO.
691 Data are presented as mean ± SEM (n =8 mice per group).*: p < 0.05, **: p < 0.01 and 
692 ***: p < 0.001, ****: p < 0.0001 compared with DSS group.
693
694 Figure 6. Concentration of CLNA and CLA in the blood, liver and colonic content.
695 (A) The composition of main fatty acids in blood. (B) The concentration of CLNA and 
696 CLA in the colonic content. (C) The concentration of CLNA1 and CLNA2 in liver.
697 Data are presented as mean ± SEM (n =8 mice per group). *: p < 0.05, **: p < 0.01 and 
698 ***: p < 0.001, ****: p < 0.0001 compared with DSS group.
699
700 Figure 7. Evaluation of Illumina MiSeq sequencing data showing that CLNA could 
701 modulate the overall structure of gut microbiota.
702  (A) Microbial distribution at the phylum level. (B) α-Diversity indicated by the Chao1 
703 index and Shannon index. (C) Cladogram. (D) Distribution histogram based on LDA, 
704 with a log LDA score above 3.0. (E) Correlation analysis of significant taxa, colitis 
705 indexes, tight junction proteins, antioxidant enzymes, cytokines in the colon and the 
706 concentration of colonic CLA. Only significant correlations (*: p < 0.05, **: p < 0.01) 
707 are displayed.
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 TABLEs 
Table 1. The composition of fatty acids of every group.
 
Group Composition
CLNA1 93.09% CLNA1 6.91% ALA
CLNA2 94.09% CLNA2 5.91%CLNA1
CLNA Mix 1.18% C18:0 3.49% C18:1 0.48% C18:2 13.23% ALA 72.65% CLNA1 8.97% CLNA2
PA Mix 76.46% PA 2.14% C9:4 3.71% C16:0 3.15% C18:0 5.94% C18:1 8.60% C18:2
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Table 3. The standard for evaluation of the disease activity index.
Weight Loss (%) Occult Blood or Gross Bleeding Stool Consistency Score
0 Negative Normal 0
1-5 Negative Loose Stool 1
6-10 Hemoccult Positive Loose Stool 2
11-15 Hemoccult Positive Diarrhea 3
＞15 Gross Bleeding Diarrhea 4
Normal stools = well formed pellets; loose stools = pasty stool that does not stick to the anus; and diarrhea = liquid stools that sticks to the anus
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